If the safety signal does spell the end of TAK-994, advantage could switch to NLS Pharmaceutics' Quilience (mazindol), a combined orexin agonist monoamine reuptake inhibitor which is also in phase ...

Mazindol ER is patent protected beyond September ... potentially reducing cravings and withdrawal symptoms without reinforcing addiction. Orexin-2 receptor ("OX2R") partial agonist: Aids in ...

The merged company plans to focus on NLS’s Dual Orexin Agonist (DOA ... including extended-release formulations of mazindol, ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

"Our research spans innovative therapeutic solutions such as Mazindol ER for fentanyl dependence, dual orexin receptor agonists for narcolepsy, and a multitarget approach to managing diabetes ...